Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Abstract Background CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated in two phase I clinical trials (CENTAURO and CENTAURO-2), showing to be...

Full description

Bibliographic Details
Main Authors: Javier Sánchez Ramírez, Yanelys Morera Díaz, Mónica Bequet-Romero, Francisco Hernández-Bernal, Yenima Martín Bauta, Katty-Hind Selman-Housein Bernal, Ana Victoria de la Torre Santos, Mariela Pérez de la Iglesia, Lian Trimiño Lorenzo, Team of Investigators of Compassionate use Program, Marta Ayala Avila
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Immunology
Subjects:
CIGB-247
VEGF cancer vaccine
Specific active immunotherapy
Humoral response
Compassionate use program
Cancer patients
Online Access:http://link.springer.com/article/10.1186/s12865-020-0338-4

Internet

http://link.springer.com/article/10.1186/s12865-020-0338-4

Similar Items